Table 4.

Adjusted hazard ratios for secondary end points and annual decline rate in eGFR in quartile subgroups stratified according to the levels of urinary potassium excretion

Secondary End Points	Quartiles of Urinary Potassium Excretion (g/d)
	Q1 (<1.72)	Q2 (1.72–2.32)	Q3 (2.33–2.90)	Q4 (>2.90)
CVD events (n=115)a	1 (Reference)	0.82 (0.50 to 1.34)	0.69 (0.40 to 1.19)	0.42 (0.22 to 0.81)
50% decline in eGFR (n=68)a	1 (Reference)	0.78 (0.40 to 1.51)	0.71 (0.35 to 1.43)	0.24 (0.08 to 0.70)
Progression to CKD stage 4 (n=32)a	1 (Reference)	0.69 (0.25 to 1.92)	0.50 (0.18 to 1.40)	0.08 (0.01 to 0.50)
Annual decline rate in eGFRb	−2.2 (−2.4 to −1.8)	−1.9 (−2.0 to −1.8)	−1.7 (−2.0 to −1.5)	−1.3c (−1.5 to −1.0)

CVD, cardiovascular disease; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile.

^aValues are adjusted hazard ratios (95% confidence intervals). Hazard ratios are adjusted for the baseline data, including age, sex, body mass index, hemoglobin A1c, total cholesterol, log triglyceride, log HDL-cholesterol, LDL-cholesterol, systolic BP, renin-angiotensin system inhibitor, hypertension, log urinary albumin excretion rate, eGFR, current smoking, and urinary sodium excretion, in the Cox proportional regression analysis.

^bData are expressed as ml/min per 1.73 m² per year (95% confidence intervals).

^cP<0.01 versus Q1 and Q2.